Skip to main content


Mark Cuban Cost Plus Drug Company aims to disrupt pharmaceutical pricing by offering a biosimilar version of Stelara, a popular drug by Johnson & Johnson, potentially making the treatment more affordable for patients.


For individuals struggling to maintain relationships despite long-term treatment, AI chatbots can provide meaningful and therapeutic assistance.


AI-powered autonomous coding is becoming a key area of contention between healthcare providers and insurance companies, as it transforms medical billing and administrative processes.


Pfizer has launched a second lawsuit targeting Novo Nordisk and the obesity biotech startup Metsera, claiming that Novo Nordisk's efforts to acquire Metsera are anticompetitive practices.


Exclusive: A detailed look into why Moderna, once a company hailed for its life-saving innovation, is currently undergoing its most severe crisis in 15 years.


The Trump administration has significantly cut the workforce of the federal agency responsible for mental health and addiction treatment, reducing its staff by over 50%.


Novo Nordisk has launched a competitive bid to acquire Metsera, a biotech company specializing in obesity treatment, aiming to surpass an offer from Pfizer. The bidding war signals increased interest and competition in the obesity-focused biotech sector.


Today's Morning Rounds brings you the latest health news, including a groundbreaking study revealing how the immune system evolves as we grow older.


Eli Lilly has formed a partnership with NVIDIA to create what is claimed to be the most powerful supercomputer owned and operated by a pharmaceutical company. This collaboration aims to leverage advanced AI technology to enhance pharmaceutical research and development capabilities.


UnitedHealth has announced a strategic shift to hire more of its doctors directly, aiming to enhance overall financial outcomes and operational control.